Skip to main content

Cell-Based Models for Neurodegeneration Study and Use in Screening

Objective

1. Treatment of neurodegenerative disease is an unmet clinical challenge and patient care is a growing, unsustainable global healthcare burden. The project will produce novel tools to address this challenge.
2. The consortium will deliver a set of innovative analytical tools for neurodegenerative drug discovery using a combination of stem cell biology and novel biomaterials assembled by additive manufacturing.
3. The toolset will be analytical kits containing induced pluripotent stem cell (iPSC)-derived human neural cells in 3D culture formats, delivered to end-users in multiwell plates ready for industrial screening.
4. Project outputs will be realised by an inter-disciplinary consortium of four SME commercial partners in three European countries, each partner supplying a specific, essential skillset.
5. iPSC-derived neural cells will be produced by Phenocell sarl (F) using stem cell differentiation protocols already shown to generate glial or neuronal cell lineages, and to reinstate donor disease phenotypes.
6. Bio-printer instrumentation and printable bio-inks to manufacture 3D scaffolds enabling 3D cell culture will be contributed by Cellink (SE).
7. 3D culture models will be customised for neural/neurodegenerative cell culture by inclusion of peptide dendrons with biological functionality using mature chemistry proprietary to Tissue Click Ltd (UK).
8. Cell-based analysis products will be validated, and made user-friendly by in situ cell cryopreservation and analytical processes familiar to AvantiCell Science Ltd (UK).
9. Each contributing technology is at TRL 6, and each has commercial utility in simpler combinations. The project assembles them in first-to-market formats beyond the current state of the art.
10. The CENSUS project output, comprising iPSC-derived neural cells cryopreserved in single-cell and co-culture 3D formats will deliver exceptional analytical precision and predictive value, unprecedented end-user convenience and strong commercial advantage

Call for proposal

H2020-FTIPilot-2016

See other projects for this call

Sub call

H2020-FTIPilot-2016-1

Coordinator

AvantiCell Science Ltd
Net EU contribution
€ 675 736,25
Address
Gibbsyard Building
KA6 5HW Ayr
United Kingdom

See on map

Region
Southern Scotland South Ayrshire
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 289 601,25

Participants (3)

PHENOCELL
France
Net EU contribution
€ 410 850,13
Address
45 Boulevard Marcel Pagnol
06130 Grasse

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Alpes-Maritimes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 176 078,62
TISSUE CLICK LTD
United Kingdom
Net EU contribution
€ 253 750,00
Address
28 Sycamore Close
BN2 6SJ Brighton

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
South East (England) Surrey, East and West Sussex Brighton and Hove
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 108 750,00
BICO GROUP AB
Sweden
Net EU contribution
€ 452 943,75
Address
Arvid Wallgrens Backe 20
413 46 Goteborg

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Södra Sverige Västsverige Västra Götalands län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 194 118,75